| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 21020a |
| Drug | Selpercatinib |
| Brand | Retsevmo® |
| Indication | Is indicated for adult and adolescent patients, 12 years and older, with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib. |
| Assessment Process | |
| Rapid review commissioned | 08/06/2021 |
| Rapid review completed | 07/07/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 22/07/2021 |
| Pre-submission consultation with Applicant | 08/11/2021 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.
